MICROBIOLOGY
mecA is a bacterial resistance gene that enables many staphylococci to withstand methicillin and nearly all other conventional β-lactam antibiotics by producing the altered penicillin-binding protein PBP2a.1 Its acquisition, usually within a mobile element called SCCmec, is the defining molecular basis of most methicillin-resistant Staphylococcus aureus (MRSA).
mecA causes resistance by replacing the normal high-affinity targets of β-lactam antibiotics with PBP2a. β-lactams normally bind penicillin-binding proteins and block transpeptidation, a key step in bacterial peptidoglycan construction. PBP2a has markedly reduced affinity for these drugs, so it can continue cell-wall cross-linking while the native proteins are inhibited. Resistance is therefore not simply a matter of producing more enzyme that destroys antibiotics; it is a target-modification mechanism. Expression may be heterogeneous: genetically resistant populations can contain cells with different levels of resistance, influenced by growth conditions, regulatory state, and additional chromosomal factors. The gene is especially consequential in Staphylococcus aureus, but it also occurs in coagulase-negative staphylococci.
mecA is usually carried on the staphylococcal cassette chromosome mec, or SCCmec. SCCmec is an integrated chromosomal element that contains the resistance determinant and cassette chromosome recombinase genes, which help mediate its insertion and movement among staphylococcal lineages.1 Different SCCmec types vary in size, accessory resistance genes, and epidemiological distribution. Large hospital-associated cassettes can carry additional antimicrobial-resistance determinants, whereas smaller cassettes are common in some community-associated lineages. The evolutionary history of MRSA reflects repeated acquisition of SCCmec by successful bacterial clones rather than the emergence of one universal strain. A distinct homolog, mecC, was identified in 2011 and explains some oxacillin-resistant isolates that lack conventional mecA.
Detection of mecA or its product is central to identifying β-lactam-resistant staphylococci. Molecular assays can detect the gene directly, while immunological tests detect PBP2a; culture-based susceptibility testing provides a phenotypic assessment. Cefoxitin is widely used as a surrogate laboratory agent because it more reliably induces and distinguishes mecA-mediated resistance than methicillin itself, whose use in routine testing has largely been replaced.3 A positive result generally predicts resistance to most penicillins, cephalosporins, and carbapenems, with carefully defined exceptions in current standards. Clinical laboratories still interpret results alongside species identification, the testing method, and local or international breakpoints. MRSA surveillance is important because infections can spread in hospitals, communities, and households.2
mecA-mediated resistance is biologically broader and diagnostically subtler than the MRSA label suggests. The gene can occur in coagulase-negative staphylococci, which are frequent skin colonizers but important causes of catheter-associated and prosthetic-device infections. Some isolates show borderline or heterogeneous resistance, making the choice of screening drug and incubation conditions consequential. Conversely, a resistant phenotype can occasionally arise from mechanisms other than mecA, so an apparently susceptible or resistant result should not be interpreted from a single molecular signal in isolation. The mecC homolog is particularly notable because routine mecA-targeted PCR assays do not detect it, while its PBP2a variant can produce a similar phenotype. SCCmec also illustrates how resistance genes can spread as linked genetic packages, coupling β-lactam resistance to other traits.1
Gene and protein names are styled in italics where appropriate; laboratory interpretation should follow the current standards adopted by the testing laboratory.
Help improve the encyclopedia. Reports go straight to the site manager.